GOECP/SEOR clinical guidelines on radiotherapy for malignant pleural mesothelioma

World J Clin Oncol. 2021 Aug 24;12(8):581-608. doi: 10.5306/wjco.v12.i8.581.ABSTRACTMalignant pleural mesothelioma (MPM) is a rare tumor with poor prognosis and rising incidence. Palliative care is common in MPM as radical treatment with curative intent is often not possible due to metastasis or extensive locoregional involvement. Numerous therapeutic advances have been made in recent years, including the use of less aggressive surgical techniques associated with lower morbidity and mortality (e.g., pleurectomy/decortication), technological advancements in the field of radiotherapy (intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic body radiotherapy, proton therapy), and developments in systemic therapies (chemotherapy and immunotherapy). These improvements have had as yet only a modest effect on local control and survival. Advances in the management of MPM and standardization of care are hampered by the evidence to date, limited by high heterogeneity among studies and small sample sizes. In this clinical guideline prepared by the oncological group for the study of lung cancer of the Spanish Society of Radiation Oncology, we review clinical, histologic, and therapeutic aspects of MPM, with a particular focus on all aspects relating to radiotherapy, including the current evidence base, associations with chemotherapy and surgery, treatment volumes and planning, technological advances, and reradiation.PMID:34513595 | PMC:PMC8394157 | DOI:10.5306/wjco.v12....
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

ConclusionThe present study showed that sarcomatoid carcinoma had a higher PD-L1 expression compared to non-small-cell lung cancer and that both PSC and MPM tended to exhibit PD-L1 positivity in the sarcomatoid compartment. Moreover, while immune checkpoint inhibitors may somewhat prolong the prognosis of both tumors, further studies with a larger cohort are necessary to confirm our results.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Inhal Toxicol. 2021 Oct 6:1-16. doi: 10.1080/08958378.2021.1971340. Online ahead of print.ABSTRACTCONTEXT: Carcinogenic properties of particulates depend, among other factors, on dimensional characteristics that affect their ability to reach sensitive tissue, to be removed or retained, and to interact with the cells.OBJECTIVE: To model mesothelioma and lung cancer potency of amphibole particles based on their dimensional characteristics and mineral habit (asbestiform vs. nonasbestiform) utilizing epidemiological data and detailed size information.METHODS: The datasets from recently created depository of dimensional informa...
Source: Inhalation Toxicology - Category: Respiratory Medicine Authors: Source Type: research
The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of patients alive at 5 years. ICIs therapies have also modified the therapeutic strategy in first-line setting in metastatic small-cell lung cancer (SCLC) patients as well as in malignant pleural mesothelioma (MPM) improving the overall survival compared with standard treatment. This phenomenon is of huge relevance as both SC...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Lung cancer Thoracic oncology Source Type: research
Decontamination efforts in Libby, Montana – the largest asbestos cleanup project in American history – moved another step closer to completion this month, according to the U.S. Environmental Protection Agency. The Montana Department of Environmental Quality and the EPA have determined that restoration efforts are complete in another major segment of the original Libby Asbestos Superfund site. A Superfund designation is defined as a federal public health emergency. Contamination at the site stemmed from the W.R. Grace &Co. vermiculite mine, once the lifeblood of the area, that spread asbestos dust thr...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS: The 6-month disease control rate did not exceed the predefined threshold, but YS110 revealed modest efficacy in response rate as salvage therapy in difficult-to-treat patients with MPM. YS110 was generally well tolerated.PMID:34590026 | PMC:PMC8474437 | DOI:10.1016/j.jtocrr.2021.100178
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
When it comes to malignant pleural mesothelioma, not everyone is treated equally. A disparity in access to care makes the difference in mesothelioma treatment quite dramatic, according to the University of Miami’s Sylvester Comprehensive Cancer Center. “Patients without access to expert multidisciplinary care at high-volume, academic facilities are being inappropriately undertreated for their disease,” medical oncologist Dr. Estelamari Rodriguez told The Mesothelioma Center at Asbestos.com. “The access is not adequate as it should be for everyone.” Rodriguez led a recent study at Univers...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
To the Editor:
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
o Comba Alessandro Marinaccio Asbestos is one of the major worldwide occupational carcinogens. The global burden of asbestos-related diseases (ARDs) was estimated around 231,000 cases/year. Italy was one of the main European asbestos producers until the 1992 ban. The WHO recommended national programs, including epidemiological surveillance, to eliminate ARDs. The present paper shows the estimate of the burden of mortality from ARDs in Italy, established for the first time. National standardized rates of mortality from mesothelioma and asbestosis and their temporal trends, based on the National Institute of Statistics...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
The publisher regrets that the authorship list was omitted from the header of this article. The correct authorship list can be found above
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Erratum Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Mesothelioma | Palliative | Palliative Care | Proton Therapy | Spain Health | Study